OBJECTIVES: To investigate the factors for continuation or withdrawal as an extension of a prospective study of @entity6731 monotherapy for the treatment of lower urinary tract symptoms suggestive of @entity1067 for more than 6  years. METHODS: A total of 104 @entity1 (age 71.5      8.2  years) were enrolled in the present study. The mean prostate volume was 44.1      23.9  mL. International Prostate Symptom Score, quality of life index, maximum flow rate, and postvoid residual urine volume were determined at baseline, and at 1, 3, 6 and 12-72  months after treatment. RESULTS: Adverse events were noted in 14 @entity1 (13.5%), and the most frequent adverse event was @entity409 (5.8%). Withdrawal was noted in 78 @entity1 , and 26 @entity1 (25.0%) were still taking @entity6731 at 72  months (continuing group). The reasons for withdrawals were: unknown in 27 @entity1 (26.0%), adverse events in nine @entity1 (8.7%), unsatisfactory effects in 30 @entity1 (28.8%) and satisfied with the current condition for six @entity1 (5.8%). In 30 @entity1 who withdrew because of unsatisfactory effects, surgery was carried out in 21 @entity1 (surgery group). The baseline total International Prostate Symptom Score did not differ between the continuing group and the surgery group. However, @entity1 with the continuing group had significantly smaller baseline prostate volume, and lower baseline quality of life index and @entity1486 , than in the surgery group. The mean total International Prostate Symptom Score, quality of life index and maximum flow rate improved significantly at 1  month, and remained stable up to 72  months. CONCLUSIONS: The withdrawal rate was higher in @entity1 with a larger prostate. The effects of @entity6731 for lower urinary tract symptoms was immediate and stable up to 72  months.

Six-year follow up of XXXX monotherapy for the treatment of lower urinary tract symptoms suggestive of @entity1067 : What are the factors for continuation or withdrawal?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6731 :: ('MESH:C095285', 'Chemical') :: ['silodosin'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia'] @entity409 :: ('MESH:D008107', 'Disease') :: ['ejaculatory dysfunction'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity6731 :: (MESH:C095285,Chemical) :: ['silodosin']
